See also this year's filing and all EDGAR filings for this company.
PDF Report 0000874015_2023_Ionis_Pharmaceuticals_INC.pdf
Logs
| warning | Large missing amount for aggregate "Liabilities" added to remainder. | industry.us_generic | {'missing_ratio': 1.4690038187305396, 'aggregate_val': 1960989000, 'exp_sum': 794243000, 'exp_to_value': {'LiabilitiesCurrent': 311561000, 'LiabilitiesNoncurrent': 473835000, 'remainder_Liabilities': 8847000}} |
| warning | Large missing amount for aggregate "Liabilities" added to remainder. | industry.us_generic | {'missing_ratio': 0.8389117629815479, 'aggregate_val': 2603386000, 'exp_sum': 1415721000, 'exp_to_value': {'LiabilitiesCurrent': 448090000, 'LiabilitiesNoncurrent': 412059000, 'remainder_Liabilities': 555572000}} |
Graph
Absolute values for 0000874015, Ionis Pharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 2,202,694,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 74,294,000 |
| 3 | remainder_Assets | 256,888,000 |
| 4 | LiabilitiesCurrent | 311,561,000 |
| 5 | LiabilitiesNoncurrent | 473,835,000 |
| 6 | remainder_Liabilities | 1,175,593,000 |
| 7 | CostOfGoodsAndServicesSold | 14,819,503 |
| 8 | SellingGeneralAndAdministrativeExpense | 140,334,979 |
| 9 | ResearchAndDevelopmentExpense | 0 |
| 10 | remainder_Expenses | 820,597,162 |
| 11 | remainder_Revenues | 645,063,799 |
| 12 | remainder_NetIncome | 10,622,467 |
| 13 | remainder_ComprehensiveNetIncome | -20,263,982 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 2,533,876,000 |
| 1 | Liabilities | 1,960,989,000 |
| 2 | Expenses | 975,751,644 |
| 3 | Revenues | 645,063,799 |
| 4 | StockholdersEquity | 572,887,000 |
| 5 | NetIncome | -320,065,378 |
| 6 | ComprehensiveNetIncome | -330,197,369 |
| 7 | BaseVar | 3,073,283,446 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 0.409 |
| 9 | EconomicCapitalRatio | 1.80 |
Edgar->Model Mapping
Feature Distribution
Change over Time
